CRISPR Trick Makes “Cold” Prostate Tumors Respond to Immunotherapy in Mice

Prostate cancer is notoriously resistant to immunotherapy — the tumours are cold, hiding from the immune system. Scientists have found a way to switch them hot, at least in mice, using a CRISPR tool that edits RNA rather than DNA.

The molecular problem

Researchers at the University of Rochester and Duke, writing in Nature Biomedical Engineering, traced the resistance to a protein called SPSB1.

In cancer cells, a shortened version of SPSB1’s messenger RNA leads to excess SPSB1, which destroys MHC-1 — the surface flag T cells rely on to recognise a tumour. No flag, no immune attack.

Why MHC-1 is the critical molecule

Every nucleated cell displays fragments of its internal proteins on MHC-1 molecules at its surface. T cells patrol by inspecting those displays, and a cell showing something abnormal — a viral protein, a mutated tumour protein — is killed.

The system depends entirely on the display existing. A cell with no MHC-1 presents nothing to inspect, so a T cell has no basis for action regardless of what the cell contains.

Losing MHC-1 is consequently one of the most common ways tumours escape immune control, and it explains why checkpoint inhibitors fail in those cases. Those drugs release brakes on T cells, which does nothing if the T cell cannot see the target in the first place.

Why RNA length matters

The mechanism turns on how messenger RNA is terminated.

An mRNA does not simply end where the protein-coding sequence stops. A trailing untranslated region follows, and it carries regulatory elements — binding sites for small RNAs and proteins that control how stable the message is and how much protein is made from it.

Cells can terminate the message early, producing a shorter version that omits some of those elements. Shortening is a normal regulatory mechanism and is widespread in cancer.

Here the shortened SPSB1 message escapes the controls that would normally limit it, so more protein is produced from the same gene — without any mutation in the gene itself.

The fix

Using CRISPR-Cas13, which targets RNA, the team forced SPSB1’s mRNA back to its normal length. That lowered SPSB1, restored MHC-1, and made the tumours visible again.

“No one has ever done this before. It’s an excellent preclinical model showing that mRNAs can be forced to re-lengthen,” said Eric J. Wagner, PhD, of the University of Rochester.

In mice, the approach dramatically improved response to immune checkpoint therapy — with no detectable off-target CRISPR effects.

Why targeting RNA rather than DNA

Cas13 cuts RNA instead of DNA, and the distinction has real advantages here.

The change is reversible. RNA is continuously produced and degraded, so an effect persists only while the tool is present — unlike a DNA edit, which is permanent and passed to daughter cells.

It is also safer in one specific respect: an off-target RNA cut damages one transcript, whereas an off-target DNA cut alters the genome permanently and could itself be oncogenic.

And in this case the problem is at the RNA level. The gene is normal; what has gone wrong is how its message is processed, which is precisely where an RNA-targeting tool belongs.

Why prostate cancer specifically

Immunotherapy has transformed outcomes in melanoma, lung cancer and several others, and has largely failed in prostate cancer.

The tumours have few mutations, so they present few abnormal fragments even when MHC-1 is intact, and the surrounding environment is immunosuppressive. Low MHC-1 compounds an already unfavourable position.

The caveats

If it holds up, re-lengthening RNA could become a new lever for making immunotherapy work in cancers that currently shrug it off.

How tumours evade immunity in other ways

MHC-1 loss is one escape route among several, and the range explains why restoring one mechanism may not be sufficient.

Tumours can reduce production of the antigens themselves, so even an intact display shows nothing abnormal. They can recruit suppressive cells — regulatory T cells and myeloid populations — that inhibit any T cell arriving. They can create a metabolic environment depleted of the nutrients T cells need to function, or acidic enough to impair them.

Checkpoint molecules are the mechanism current drugs address, and their success established that a single evasion route can sometimes be the limiting one.

Most tumours use several simultaneously, which is the practical difficulty. Restoring MHC-1 in a tumour that also excludes T cells physically, or suppresses them on arrival, would make the cancer visible to an immune system still unable to act.

That is an argument for combination rather than against the approach. It also means a preclinical result showing dramatic improvement in a mouse model — where the tumour is typically newly implanted and less elaborately defended than a human cancer that has coexisted with an immune system for years — should be read as demonstrating the mechanism rather than predicting the clinical effect.

This is early, preclinical work in mice, and RNA-editing therapies face real delivery and safety hurdles. Getting a Cas13 system into tumour cells throughout the body, in enough of them, sustained long enough to matter, is unsolved — and delivery has been the limiting factor for RNA therapeutics generally. Research news, not medical advice.